Filtered By:
Source: EurekAlert! - Infectious and Emerging Diseases
Infectious Disease: Coronavirus
This page shows you your search results in order of date.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Monoclonal antibodies against MERS coronavirus show promise in phase 1 NIH-sponsored trial
(NIH/National Institute of Allergy and Infectious Diseases) A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes MERS found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical company Regeneron. The trial was sponsored by NIAID.
Source: EurekAlert! - Infectious and Emerging Diseases - February 23, 2021 Category: Infectious Diseases Source Type: news
NIH officials highlight COVID-19 vaccine facts, unknowns for healthcare providers
(NIH/National Institute of Allergy and Infectious Diseases) Healthcare providers must be able to explain the latest data supporting the safety and efficacy of vaccines for coronavirus disease 2019 (COVID-19) so they can strongly encourage vaccination when appropriate while acknowledging that uncertainty and unknowns remain. This message comes from a new commentary co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and other leading NIAID scientists in the journalAnnals of Internal Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2021 Category: Infectious Diseases Source Type: news
Peer-reviewed report on Moderna COVID-19 vaccine publishes
(NIH/National Institute of Allergy and Infectious Diseases) The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in theNew England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).
Source: EurekAlert! - Infectious and Emerging Diseases - December 30, 2020 Category: Infectious Diseases Source Type: news
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
(NIH/National Institute of Allergy and Infectious Diseases) The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. NIAID and BARDA are funding the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - December 28, 2020 Category: Infectious Diseases Source Type: news
Study of coronavirus infection & multisystem inflammatory syndrome in children begins
(NIH/National Institute of Allergy and Infectious Diseases) An observational study has launched to evaluate the short- and long-term health outcomes of SARS-CoV-2 infection in children, including multisystem inflammatory syndrome in children, and to characterize the immunologic pathways associated with different disease presentations and outcomes. SARS-CoV-2 is the virus that causes COVID-19. The study, called the Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (PRISM), will enroll at least 250 children and young adults ages 20 years or younger.
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news
NIH trial testing hyperimmune intravenous immunoglobulin and remdesivir to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
Source: EurekAlert! - Infectious and Emerging Diseases - October 8, 2020 Category: Infectious Diseases Source Type: news
Fourth large-scale COVID-19 vaccine trial begins in the United States
(NIH/National Institute of Allergy and Infectious Diseases) A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers. The trial is designed to evaluate if the investigational Janssen COVID-19 vaccine (JNJ-78436725) can prevent symptomatic COVID-19 after a single dose regimen. Up to 60,000 volunteers will be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.
Source: EurekAlert! - Infectious and Emerging Diseases - September 23, 2020 Category: Infectious Diseases Source Type: news
Chimeron Bio & George Mason NCBID partner on COVID-19 vaccine using ChaESARTM technology
(George Mason University) RNA therapeutics company, Chimeron Bio and George Mason University's National Center for Biodefense and Infectious Diseases (NCBID) announced their partnership to develop a Coronavirus (COVID-19) vaccine based on Chimeron Bio's ChaESARTM self-amplifying RNA technology and will integrate Mason's complimenting expertise and Biomedical Research Laboratory (BRL), a National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) supported, state-of-the-art Regional Biocontainment Laboratory for the rapid screening of the company's vaccine pipeline.
Source: EurekAlert! - Infectious and Emerging Diseases - May 29, 2020 Category: Infectious Diseases Source Type: news
NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study.
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2020 Category: Infectious Diseases Source Type: news
Study to determine incidence of novel coronavirus infection in US children begins
(NIH/National Institute of Allergy and Infectious Diseases) A study to help determine the rate of novel coronavirus infection in children and their family members in the United States has begun enrolling participants. The study, called Human Epidemiology and Response to SARS-CoV-2 (HEROS), also will help determine what percentage of children infected with SARS-CoV-2, the virus that causes COVID-19, develop symptoms of the disease.
Source: EurekAlert! - Infectious and Emerging Diseases - May 4, 2020 Category: Infectious Diseases Source Type: news
New coronavirus stable for hours on surfaces
(NIH/National Institute of Allergy and Infectious Diseases) The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study from National Institutes of Health, CDC, UCLA and Princeton University scientists in NEJM. They found that (SARS-CoV-2) was detectable in aerosols for up to three hours, up to four hours on copper, up to 24 hours on cardboard and up to two to three days on plastic and stainless steel.
Source: EurekAlert! - Infectious and Emerging Diseases - March 17, 2020 Category: Infectious Diseases Source Type: news
NIH clinical trial of remdesivir to treat COVID-19 begins
(NIH/National Institute of Allergy and Infectious Diseases) A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center in Omaha. The trial regulatory sponsor is the National Institute of Allergy and Infectious Diseases. This is the first clinical trial in the US to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in China.
Source: EurekAlert! - Infectious and Emerging Diseases - February 25, 2020 Category: Infectious Diseases Source Type: news
Remdesivir prevents MERS coronavirus disease in monkeys
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.
Source: EurekAlert! - Infectious and Emerging Diseases - February 13, 2020 Category: Infectious Diseases Source Type: news
NIAID officials discuss novel Coronavirus that recently emerged in China
(NIH/National Institute of Allergy and Infectious Diseases) The new cluster of viral pneumonia cases originating in Wuhan, China, marks the third time in 20 years that a member of the large family of coronaviruses (CoVs) has jumped from animals to humans and sparked an outbreak. In a new JAMA Viewpoint essay, Anthony S. Fauci, M.D., director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), looks back at two earlier novel CoV outbreaks that initially caused global havoc and describes steps needed to contain the current one.
Source: EurekAlert! - Infectious and Emerging Diseases - January 23, 2020 Category: Infectious Diseases Source Type: news
NIH study shows how MERS Coronavirus evolves to infect different species
(NIH/National Institute of Allergy and Infectious Diseases) New research published in Cell Reports from scientists at the National Institute of Allergy and Infectious Diseases (NIAID) shows how MERS-CoV can adapt to infect cells of a new species, which suggests that other coronaviruses might be able to do the same.
Source: EurekAlert! - Infectious and Emerging Diseases - August 14, 2018 Category: Infectious Diseases Source Type: news
